1 / 14

Surrogate Endpoints and Non-randomized Trials

Surrogate Endpoints and Non-randomized Trials. Roseann White Humble Biostatistician. Type of non-randomized trials. Diagnostic/Natural History trial Single arm trial that shows superiority/non-inferiority in clinical endpoint Example: Safety concerns for placebo or current practice.

hisa
Download Presentation

Surrogate Endpoints and Non-randomized Trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician

  2. Type of non-randomized trials • Diagnostic/Natural History trial • Single arm trial that shows superiority/non-inferiority in clinical endpoint Example: Safety concerns for placebo or current practice

  3. Motivation • Chiron Corporation developed a method to measure the amount of HIV-1 virus in the blood • To obtain approval from FDA for the device, Chiron needed to demonstrate clinical utility • Investigators also saw the potential for Viral Load to be a surrogate for HIV-1 disease progression

  4. Prentice Criteria for a surrogate endpoint Re-statement of Prentice Criteria for a surrogate endpoint • Baseline measurements are predictive of outcome • Changes in the measurement over time is predictive of outcome • Changes in the measurement to external forces (therapy) is predictive of outcome What if there is no therapy?

  5. Non-randomized trial – a prospective analysis of a retrospective cohort • Description of Cohorts • 180 seropositive men studied for more than 10 years from the Pittsburgh portion of Multicenter AIDS Cohort Study (MACS)– Mellors, J.W., et. al. Science, 272 • 1604 men infected with HIV-1 from four university-based clinical centers participating in MACS – Mellors, J.W. et. al. Annals of Internal Medicine, 126 • ~250 patients from New York Blood Center as part of a PMA submission for the bDNA diagnostic • Analysis • Logistic regression using baseline values to predict survival • Cox proportional hazards model with HIV-1 viral load as a time dependant covariate • Treatment effect?

  6. Predictive in stratified populations • Reprinted from Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection • John W. Mellors, et.al.Annals 1997 126: 946-954.

  7. Rest of the story • Viral load was used along with CD4 counts as evidence of efficacy for accelerated approval of the protease inhibitors • Many efficacy trials measured viral load along with CD4 count • FDA Guidance to the industry (2002) recommended the use of viral load for efficacy in accelerated approvals • “The Evaluation of Surrogate Endpoints in Practice: Experience in HIV”* by Michael Hughes • Uses several different methods to “validate” HIV viral load and CD4 counts as surrogate endpoints *Chapter 17 in The Evaluation of Surrogate Endpoints edited by T. Burzykowski, et. al. Springer, 2005

  8. Types of non-randomized trials • Quantitative Diagnostic • Single arm trial to show superiority or non-inferiority in clinical endpoint

  9. Motivation • Randomization is difficult • Cost prohibitive • Concerns for the safety of the patient • Limited population available for recruitment • Potential surrogate endpoints available what's a statistician to do?

  10. Design Considerations • Evaluate the risk associated with the surrogate for the product in question • If it’s a second generation product, will the surrogate reflect the improvements in the product AND • Will the surrogate reflect potential problems? Example: Using angiographic binary restenosis as a surrogate at 6 months for drug eluting stent whose drug has not completely eluted at six months

  11. Design Considerations (con’t) • Choice of comparison – Historical Control versus Objective Performance Criteria • Historical Control provides more of an opportunity to demonstrate that the current trial population is similar to the historical population in which the surrogate was based. • When using an objective performance criteria, develop a detailed method in which you will “validate” the current population is reflective of the population that surrogate was based. • Subgroup analysis where the surrogate shows difference, e.g. diabetics versus non-diabetics

  12. Design Considerations (con’t) • Consider a co-primary clinical endpoint where you demonstrate a trend in the same direction as your surrogate • Less stringent alpha for superiority • Wider delta for non-inferiority

  13. Conclusion • Validation of Surrogates endpoint using non-randomized trials is challenging • More work needs to be done to develop techniques that do not necessarily require a very effective treatment • Use of surrogates in single arm trials requires: • Careful consideration as to whether the surrogate will reflect the true performance of the product • Use of a historical control or a detail plan of how to assure the current population reflect the population on which the surrogate was based.

More Related